04 Sep 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/immunic-announces-first-patient-enrolled-in-investigator-sponsored-phase-2-clinical-trial-of-vidofludimus-calcium-in-patients-with-post-covid-syndrome-302237781.html
https://www.prnewswire.com/news-releases/immunic-receives-notice-of-allowance-for-united-states-patent-protecting-the-treatment-of-relapsing-multiple-sclerosis-with-vidofludimus-and-its-salts-301975455.html
16 Oct 2023
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/immunic-presents-data-from-phase-2-caldose-1-trial-of-vidofludimus-calcium-in-ulcerative-colitis-at-the-united-european-gastroenterology-week-2023-301956189.html
17 Aug 2023
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/immunic-completes-enrollment-of-its-phase-2-calliper-trial-of-vidofludimus-calcium-in-progressive-multiple-sclerosis-301903416.html
07 Apr 2023
// Paul Schloesser ENDPTS
https://endpts.com/immunic-touts-positive-data-in-maintenance-phase-of-failed-phii-trial/
05 Apr 2023
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/immunic-reports-positive-data-from-maintenance-phase-of-phase-2-caldose-1-trial-of-vidofludimus-calcium-in-moderate-to-severe-ulcerative-colitis-301790538.html
LOOKING FOR A SUPPLIER?